Permanent pacing versus cardioneuroablation for cardioinhibitory vasovagal syncope.

IF 2.6 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Rakesh Gopinathannair, Brian Olshansky, Mohit K Turagam, Sandeep Gautam, Piotr Futyma, Krishna Akella, Halil Ibrahim Tanboga, Serdar Bozyel, Kivanc Yalin, Deepak Padmanabhan, Jayaprakash Shenthar, Dhanunjaya Lakkireddy, Tolga Aksu
{"title":"Permanent pacing versus cardioneuroablation for cardioinhibitory vasovagal syncope.","authors":"Rakesh Gopinathannair, Brian Olshansky, Mohit K Turagam, Sandeep Gautam, Piotr Futyma, Krishna Akella, Halil Ibrahim Tanboga, Serdar Bozyel, Kivanc Yalin, Deepak Padmanabhan, Jayaprakash Shenthar, Dhanunjaya Lakkireddy, Tolga Aksu","doi":"10.1007/s10840-022-01456-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We compared the efficacy and safety of cardioneuroablation (CNA) vs. permanent pacing (PM) for recurrent cardioinhibitory vasovagal syncope (CI-VVS).</p><p><strong>Methods: </strong>One hundred sixty-two patients (CNA = 61, PM = 101), age 36 + 11 years) with syncope frequency of 6.7 ± 3.9/year were included in this multicenter study. All patients with CNA were provided by a single center, while patients with PM were provided by 4 other centers. In the CNA arm, an electroanatomic mapping guided approach was used to detect and ablate ganglionated plexus sites. Dual chamber rate drop response (RDR) or close loop stimulation (CLS) transvenous and leadless pacemakers were implanted using standard technique. The primary endpoint was freedom from syncope.</p><p><strong>Results: </strong>Of 101 patients in the PM group, 39 received dual-chamber pacemaker implants with the CLS algorithm, 38 received dual-chamber pacemakers with the RDR algorithm, and 24 received a leadless pacemaker. At 1-year follow-up, 97% and 89% in the CNA and PM group met the primary endpoint (adjusted HR = 0.27, 95% CI 0.06-1.24, p = 0.09). No significant differences in adverse events were noted between groups. There was no significant association between age (HR:1.01, 95% CI 0.96-1.06, p = 0.655), sex (HR:1.15, 95% CI 0.38-3.51, p = 0.809), and syncope frequency in the past year (HR:1.10, 95% CI 0.97-1.25, p = 0.122) and the primary outcome in univariable analyses.</p><p><strong>Conclusions: </strong>After adjustment for patient characteristics, the medium-term syncope recurrence risk of CI-VVS patients who underwent CNA was similar to that of a population of patients undergoing pacemaker implantation with a similar safety profile.</p>","PeriodicalId":16202,"journal":{"name":"Journal of Interventional Cardiac Electrophysiology","volume":" ","pages":"203-210"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Interventional Cardiac Electrophysiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10840-022-01456-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/12/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: We compared the efficacy and safety of cardioneuroablation (CNA) vs. permanent pacing (PM) for recurrent cardioinhibitory vasovagal syncope (CI-VVS).

Methods: One hundred sixty-two patients (CNA = 61, PM = 101), age 36 + 11 years) with syncope frequency of 6.7 ± 3.9/year were included in this multicenter study. All patients with CNA were provided by a single center, while patients with PM were provided by 4 other centers. In the CNA arm, an electroanatomic mapping guided approach was used to detect and ablate ganglionated plexus sites. Dual chamber rate drop response (RDR) or close loop stimulation (CLS) transvenous and leadless pacemakers were implanted using standard technique. The primary endpoint was freedom from syncope.

Results: Of 101 patients in the PM group, 39 received dual-chamber pacemaker implants with the CLS algorithm, 38 received dual-chamber pacemakers with the RDR algorithm, and 24 received a leadless pacemaker. At 1-year follow-up, 97% and 89% in the CNA and PM group met the primary endpoint (adjusted HR = 0.27, 95% CI 0.06-1.24, p = 0.09). No significant differences in adverse events were noted between groups. There was no significant association between age (HR:1.01, 95% CI 0.96-1.06, p = 0.655), sex (HR:1.15, 95% CI 0.38-3.51, p = 0.809), and syncope frequency in the past year (HR:1.10, 95% CI 0.97-1.25, p = 0.122) and the primary outcome in univariable analyses.

Conclusions: After adjustment for patient characteristics, the medium-term syncope recurrence risk of CI-VVS patients who underwent CNA was similar to that of a population of patients undergoing pacemaker implantation with a similar safety profile.

永久起搏与心脏神经消融术治疗心脏抑制性血管迷走性晕厥。
背景:我们比较了心脏神经消融术(CNA)与永久起搏术(PM)治疗复发性心脏抑制性血管迷走性晕厥(CI-VVS)的有效性和安全性:这项多中心研究共纳入 162 名晕厥频率为 6.7 ± 3.9 次/年的患者(CNA = 61 人,PM = 101 人)(年龄为 36 + 11 岁)。所有 CNA 患者均由一个中心提供,而 PM 患者则由其他 4 个中心提供。在 CNA 治疗组中,采用电解剖图引导法检测并消融神经节丛部位。采用标准技术植入双腔速率下降反应(RDR)或闭环刺激(CLS)经静脉和无导联起搏器。主要终点是免于晕厥:在 PM 组的 101 名患者中,39 人接受了采用 CLS 算法的双腔起搏器植入,38 人接受了采用 RDR 算法的双腔起搏器,24 人接受了无导联起搏器。随访 1 年时,CNA 组和 PM 组分别有 97% 和 89% 的患者达到了主要终点(调整后 HR = 0.27,95% CI 0.06-1.24,p = 0.09)。各组之间的不良反应无明显差异。在单变量分析中,年龄(HR:1.01,95% CI 0.96-1.06,p = 0.655)、性别(HR:1.15,95% CI 0.38-3.51,p = 0.809)和过去一年晕厥频率(HR:1.10,95% CI 0.97-1.25,p = 0.122)与主要结局之间无明显关联:在对患者特征进行调整后,接受CNA治疗的CI-VVS患者的中期晕厥复发风险与接受起搏器植入术的患者相似,且安全性相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.30
自引率
11.10%
发文量
320
审稿时长
4-8 weeks
期刊介绍: The Journal of Interventional Cardiac Electrophysiology is an international publication devoted to fostering research in and development of interventional techniques and therapies for the management of cardiac arrhythmias. It is designed primarily to present original research studies and scholarly scientific reviews of basic and applied science and clinical research in this field. The Journal will adopt a multidisciplinary approach to link physical, experimental, and clinical sciences as applied to the development of and practice in interventional electrophysiology. The Journal will examine techniques ranging from molecular, chemical and pharmacologic therapies to device and ablation technology. Accordingly, original research in clinical, epidemiologic and basic science arenas will be considered for publication. Applied engineering or physical science studies pertaining to interventional electrophysiology will be encouraged. The Journal is committed to providing comprehensive and detailed treatment of major interventional therapies and innovative techniques in a structured and clinically relevant manner. It is directed at clinical practitioners and investigators in the rapidly growing field of interventional electrophysiology. The editorial staff and board reflect this bias and include noted international experts in this area with a wealth of expertise in basic and clinical investigation. Peer review of all submissions, conflict of interest guidelines and periodic editorial board review of all Journal policies have been established.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信